Comprehending the influence of sarcopenia on the efficacy of PD-1 inhibitors is essential for identifying strategies to mitigate this impact and enhance treatment outcomes in patients with NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.